Clinical Trial Update: Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial evaluating subcutaneous homoharringtonine (omacetaxine mepesuccinate) in patients with advanced chronic myeloid leukemia has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Homoharringtonine (omacetaxine mepesuccinate) (omacetaxine mepesuccinate)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2014-06-30